Therapeutical approach to dry eye syndrome

Stanković-Babić, Gordana; Zlatanović, Gordana; Jocić, Jasmina Dordević; Cekić, Sonja; Vujanović, Milena

doi:10.2298/mpns1012793s

Cited by 6 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Currently, the main therapy for dry eye is artificial tears, with anti-inflammatory therapy and punctual occlusion therapy as second and third line therapies. 5 …”

Section: Introductionmentioning

confidence: 99%

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye

Park

Song

Choi

et al. 2017

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To investigate the efficacy of 0.1%, 0.15%, and 0.3% sodium hyaluronate (SH) artificial tears compared with 0.05% cyclosporine (CS) ophthalmic solution for the treatment of dry eye.Methods: One hundred seventy-six patients were recruited and randomized to receive of 0.1%, 0.15%, and 0.3% SH and 0.05% CS. There was a primary end point which is the changes in the fluorescein corneal staining (FCS) score to determine noninferiority of 0.1%, 0.15%, and 0.3% SH. Secondary objective end points were lissamine green conjunctival staining (LGCS) scores, Schirmer test, and tear film break-up time (TBUT). Secondary subjective end point was ocular surface disease index (OSDI) score. These were evaluated before treatment and 6 and 12 weeks after start of treatment.Results: In the primary analysis, the mean change from baseline in FCS scores verified noninferiority of 0.1% and 0.15% SH to 0.05% CS and also indicated significant improvement of all groups (P < 0.05). Values for TBUT, LGCS scores, and OSDI scores showed significant improvements in all groups (P < 0.05), although no significant intergroup difference was shown. However, Schirmer test scores in the 0.15% SH group showed a significant tendency for better improvement at week 12 compared with the other groups (P < 0.05). No serious adverse events were observed.Conclusions: Administration of 0.1%, 0.15%, and 0.3% SH was effective in improving both the objective signs and subjective symptoms of dry eye. Those findings, in addition to the well-tolerated profile of 0.1%, 0.15%, and 0.3% SH, show that it is effective therapeutic method for dry eye.

show abstract

“…4 Currently, the main therapy for dry eye is artificial tears, with anti-inflammatory therapy and punctual occlusion therapy as second and third line therapies. 5 …”

Section: Introductionmentioning

confidence: 99%

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye

Park

Song

Choi

et al. 2017

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Androgen plays an important role in the pathogenesis of xerophthalmia and its mechanism is also involved in immune inflammation. Androgens have immunosuppressive effects and can maintain the balance of pro-inflammatory factors and antiinflammatory factors in ocular surface tissues and glands, while the imbalance of androgens will increase the pro-inflammatory factors and cause eye discomfort (Babić et al, 2010;Knop and Knop, 2010;Li and Pflugfelder, 2005). The decrease of androgen level will lead to the atrophy of lacrimal epithelial cells, the disappearance of acinus mucus, the decrease of conjunctival goblet cells, the decrease of mucin expression, the shorten of tear film rupture time, and the decrease of tear quality and quantity (Sullivan et al, 2006).…”

Section: List the Factors Of Ded Pathogenesis And Immune Inflammation Sex Hormone And Immune Inflammationmentioning

confidence: 99%

Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms

Dong

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Dry eye disease is a common and frequently occurring ophthalmology with complex and diverse causes, and its incidence is on the upward trend. The pathogenesis of DED is still completely clear. However, the immune response based on inflammation has been recognized as the core basis of this disease. In this review, we will systematically review the previous research on the treatment of DED in immune inflammation, analyze the latest views and research hotspots, and provide reference for the prevention and treatment of DED.

show abstract

“…Lacrimal gland dysfunction can also arise from inflammation triggered by the dry environment, auto-immune attack as in Sjogren’s syndrome and rheumatoid arthritis, side effects of chemo and radiation therapies, as well as congenital defects (Javadi and Feizi, 2011; He et al, 2013; Park et al, 2015). Several treatments exist, including punctal occlusion to reduce tear drainage, anti-inflammatory drugs such as topical cyclosporine and lifitegrast, and most commonly artificial tears and gels (Babic et al, 2010). However, each of these clinical interventions are primarily palliative, and are not aimed at curing the underlying lacrimal gland deficiency.…”

Section: Overview Of the Lacrimal Glandmentioning

confidence: 99%

Lacrimal gland development: From signaling interactions to regenerative medicine

Garg

Zhang

2017

Developmental Dynamics

View full text Add to dashboard Cite

The lacrimal gland plays a pivotal role in keeping the ocular surface lubricated, and protecting it from environmental exposure and insult. Dysfunction of the lacrimal gland results in deficiency of the aqueous component of the tear film, which can cause dryness of the ocular surface, also known as the aqueous-deficient dry eye disease. Left untreated, this disease can lead to significant morbidity, including frequent eye infections, corneal ulcerations and vision loss. Current therapies do not treat the underlying deficiency of the lacrimal gland, but merely provide symptomatic relief. To develop more sustainable and physiological therapies, such as in vivo lacrimal gland regeneration or bioengineered lacrimal gland implants, a thorough understanding of lacrimal gland development at the molecular level is of paramount importance. Based on the structural and functional similarities between rodent and human eye development, extensive studies have been undertaken to investigate the signaling and transcriptional mechanisms of lacrimal gland development using mouse as a model system. In this review, we describe the current understanding of the extrinsic signaling interactions and the intrinsic transcriptional network governing lacrimal gland morphogenesis, as well as recent advances in the field of regenerative medicine aimed at treating dry eye disease.

show abstract

Therapeutical approach to dry eye syndrome

Cited by 6 publications

References 37 publications

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye

Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms

Lacrimal gland development: From signaling interactions to regenerative medicine

Contact Info

Product

Resources

About